Trials / Withdrawn
WithdrawnNCT04864977
A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes
Novel Approach for Basal Insulin Titration: A Proof-of-Concept Study
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate a novel approach for insulin glargine (LY2963016) titration for insulin-naïve adults with type 2 diabetes (T2D) The study will last about 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Basal Insulin | Participants administered basal insulin |
Timeline
- Start date
- 2021-08-16
- Primary completion
- 2022-06-06
- Completion
- 2022-06-06
- First posted
- 2021-04-29
- Last updated
- 2021-08-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04864977. Inclusion in this directory is not an endorsement.